INVA Quote, Financials, Valuation and Earnings

Merck & Co., Inc. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of 18.15%. Innoviva, Inc.'s return on equity of 32.01% beat Merck & Co., Inc.'s return on equity of 36.76%.

Innoviva, Inc. has a consensus price target of $33.20, signalling upside risk potential of 44.41%. On the other hand Merck & Co., Inc. has an analysts' consensus of $128.59 which suggests that it could grow by 6.11%. Given that Innoviva, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Innoviva, Inc. is more attractive than Merck & Co., Inc..

Innoviva, Inc. has a beta of 0.402, which suggesting that the stock is 59.814% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.446%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 4.42%. Merck & Co., Inc. offers a yield of 2.74% to investors and pays a quarterly dividend of $0.85 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Innoviva, Inc. quarterly revenues are $118M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. Innoviva, Inc.'s net income of $164.2M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Innoviva, Inc.'s price-to-earnings ratio is 7.40x while Merck & Co., Inc.'s PE ratio is 16.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 4.22x versus 4.67x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of -165.45%. Innoviva, Inc.'s return on equity of 32.01% beat Nektar Therapeutics's return on equity of -364.32%.

Innoviva, Inc. has a consensus price target of $33.20, signalling upside risk potential of 44.41%. On the other hand Nektar Therapeutics has an analysts' consensus of $128.13 which suggests that it could grow by 66.42%. Given that Nektar Therapeutics has higher upside potential than Innoviva, Inc., analysts believe Nektar Therapeutics is more attractive than Innoviva, Inc..

Innoviva, Inc. has a beta of 0.402, which suggesting that the stock is 59.814% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.165, suggesting its more volatile than the S&P 500 by 16.45%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 4.42%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Innoviva, Inc. quarterly revenues are $118M, which are larger than Nektar Therapeutics quarterly revenues of $21.8M. Innoviva, Inc.'s net income of $164.2M is higher than Nektar Therapeutics's net income of -$36.1M. Notably, Innoviva, Inc.'s price-to-earnings ratio is 7.40x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 4.22x versus 93.68x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Oramed Pharmaceuticals, Inc. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of -382.1%. Innoviva, Inc.'s return on equity of 32.01% beat Oramed Pharmaceuticals, Inc.'s return on equity of 37.58%.

Innoviva, Inc. has a consensus price target of $33.20, signalling upside risk potential of 44.41%. On the other hand Oramed Pharmaceuticals, Inc. has an analysts' consensus of $3.25 which suggests that it could grow by 82.75%. Given that Oramed Pharmaceuticals, Inc. has higher upside potential than Innoviva, Inc., analysts believe Oramed Pharmaceuticals, Inc. is more attractive than Innoviva, Inc..

Innoviva, Inc. has a beta of 0.402, which suggesting that the stock is 59.814% less volatile than S&P 500. In comparison Oramed Pharmaceuticals, Inc. has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.392%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 4.42%. Oramed Pharmaceuticals, Inc. offers a yield of 7.25% to investors and pays a quarterly dividend of $0.25 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Oramed Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Innoviva, Inc. quarterly revenues are $118M, which are larger than Oramed Pharmaceuticals, Inc. quarterly revenues of --. Innoviva, Inc.'s net income of $164.2M is higher than Oramed Pharmaceuticals, Inc.'s net income of $9.2M. Notably, Innoviva, Inc.'s price-to-earnings ratio is 7.40x while Oramed Pharmaceuticals, Inc.'s PE ratio is 2.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 4.22x versus 71.42x for Oramed Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of 21.74%. Innoviva, Inc.'s return on equity of 32.01% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Innoviva, Inc. has a consensus price target of $33.20, signalling upside risk potential of 44.41%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $872.70 which suggests that it could grow by 14.55%. Given that Innoviva, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Innoviva, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Innoviva, Inc. has a beta of 0.402, which suggesting that the stock is 59.814% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.238%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 4.42%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.94 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Innoviva, Inc. quarterly revenues are $118M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Innoviva, Inc.'s net income of $164.2M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Innoviva, Inc.'s price-to-earnings ratio is 7.40x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 4.22x versus 5.66x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.